Loqtorzi (toripalimab-tpzi) sold under the brand name 拓益 in china, is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.
Chinese Version
Brand name：Loqtorzi (拓益)
INN name：Toripalimab (特瑞普利单抗)
Manufacturer：Junshi Biosciences (君实生物)
Packaging：240mg*6ml/Box
Inquire&E-mail: care@100pei.com
On October 27, 2023, The FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
扫一扫 
